Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 ...

U.S. INDICATIONS AND USAGE POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) ...

H. Lundbeck A/S (Lundbeck) is advancing leadership in migraine with a comprehensive collection of datasets to be presented at the 2025 International Headache Congress, taking place in São Paulo (Sept ...

Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

At a $10 million valuation, SEGG Media’s July 2025 acquisition of a 51% controlling stake in DotCom Ventures Inc., which owns Concerts.com and TicketStub.com strategically positioned the Company to ...

Dauvilliers Y, Antczak J, Buntinx E, et al. Efficacy and safety of Oveporexton (TAK-861) for the treatment of narcolepsy type 1: results from a phase 3 randomized study in Asia, Australia, and Europe.

Underscoring how common the practice is, ProPublica found that at least three of Trump’s Cabinet members call multiple homes ...

AL-S Pharma said the trial met the primary endpoints and showed a clinically meaningful change in secondary endpoints.

By 7:30 p.m. on Tuesday, Sept. 9, polls throughout Charlotte would close -- though anyone in line to vote by 7:30 p.m. was ...